Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
Open Access
- 19 November 2014
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 56 (6), 1643-1650
- https://doi.org/10.3109/10428194.2014.957203
Abstract
Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence of second cancers, but the contribution of commonly used frontline therapies to the incidence of second cancers is unclear. We report on the characteristics, incidence, outcomes and factors associated with second cancers in 234 patients receiving fludarabine, cyclophosphamide and rituximab (FCR) based regimens in the frontline setting. The risk of second cancers was 2.38 times higher than the expected risk in the general population. Ninety-three patients (40%) had other cancers before and 66 patients (28%) after FCR. Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) (5.1%) and Richter transformation (RT) (9%) were high, while solid tumors were not increased. Overall survival of patients with second cancers after frontline FCR was shorter (median of 4.5 years) compared to patients with and without prior cancers. Second cancer risk after frontline FCR is mainly due to high rates of t-AML/MDS and RT, and as speculated the survival of affected patients is shorter.This publication has 60 references indexed in Scilit:
- Cancer risk with alemtuzumab following kidney transplantationClinical Transplantation, 2013
- Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based studyBritish Journal of Cancer, 2011
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- High Recurrence Rates of Squamous Cell Carcinoma after Mohs' Surgery in Patients with Chronic Lymphocytic LeukemiaDermatologic Surgery, 2006
- Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemiaJournal of the American Academy of Dermatology, 2005
- Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemiaLeukemia & Lymphoma, 2005
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Aggressive growth of epithelial carcinomas following treatment with nucleoside analoguesAmerican Journal of Hematology, 2002
- Flare-Up of Squamous Cell Carcinoma of the Skin following Fludarabine Therapy for Chronic Lymphocytic LeukemiaActa Haematologica, 1997